IL27抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07379(IL27 Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P07379(IL27 Antibody) at dilution 1/15. (Original magnification: ×200)    

  
  

IL-27 is a heterodimeric cytokine composed of p28 and Epstein-Barr virus-induced gene 3 (EBI3) subunits, primarily secreted by antigen-presenting cells such as dendritic cells and macrophages. It signals through a receptor complex comprising IL-27Rα (WSX-1) and gp130. activating downstream pathways like JAK-STAT, which regulate immune responses. IL-27 plays dual roles in immunity, balancing pro-inflammatory and anti-inflammatory effects. It promotes Th1 differentiation and antiviral responses while suppressing Th17 and Th2 cells, making it critical in autoimmune diseases, infections, and cancer. Dysregulated IL-27 signaling is linked to conditions like multiple sclerosis, inflammatory bowel disease, and certain cancers.

IL-27 antibodies are tools to modulate or detect IL-27 activity. Neutralizing antibodies block IL-27/receptor interactions, potentially curbing its pro-inflammatory effects in autoimmune disorders or enhancing antitumor immunity in cancer. Conversely, agonist antibodies might exploit IL-27’s anti-inflammatory properties to treat chronic inflammation. Diagnostic antibodies aid in quantifying IL-27 levels in research or clinical settings. Preclinical studies using IL-27 antibodies in models like experimental autoimmune encephalomyelitis (EAE) or colitis show therapeutic promise, though clinical translation remains limited. Challenges include IL-27’s context-dependent functions, necessitating precise targeting strategies. Research continues to clarify its mechanistic nuances and optimize antibody-based interventions.